Shuttle Pharma's SP-1-303: A Promising HDAC Inhibitor for Breast Cancer Treatment

Shuttle Pharmaceuticals Holdings, Inc., a specialty pharmaceutical company, has published a manuscript highlighting the potential of its HDAC inhibitor, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression, leading to substantial growth inhibition of estrogen receptor positive breast cancer cells.

The study, published in PLOS ONE, was conducted by Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Principal Scientist at Shuttle Pharma. SP-1-303 is a selective Class I HDAC inhibitor that inhibits HDAC1, 3, and 6 and has direct cellular toxicity in estrogen receptor positive breast cancer cells. It also increases PD-L1 expression levels in a time-dependent manner, supporting the combination of SP-1-303 with an immune checkpoint blocker to enhance therapeutic benefits.

Anatoly Dritschilo, CEO of Shuttle Pharmaceuticals, said that the report highlights the scientific and financial community's interest in the combined targeting of Class I HDACs and ATM by SP-1-303 as a promising therapeutic approach for treating estrogen receptor positive breast cancers and supports further preclinical evaluation as a potential therapeutic agent.